These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29971404)

  • 21. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 22. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 23. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 24. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 26. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
    Greener M
    EMBO Rep; 2005 Mar; 6(3):202-4. PubMed ID: 15741969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Making medicines safer--the need for an independent drug safety board.
    Wood AJ; Stein CM; Woosley R
    N Engl J Med; 1998 Dec; 339(25):1851-4. PubMed ID: 9854125
    [No Abstract]   [Full Text] [Related]  

  • 29. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 31. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early experience with the FDA's Breakthrough Devices program.
    Johnston JL; Dhruva SS; Ross JS; Rathi VK
    Nat Biotechnol; 2020 Aug; 38(8):933-938. PubMed ID: 32704171
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 34. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 35. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 36. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 37. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 38. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice.
    Deyo RA
    J Am Board Fam Pract; 2004; 17(2):142-9. PubMed ID: 15082674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commemorating the 50th anniversary of the Drug Amendments of 1962.
    Hutt PB; Temple R
    Food Drug Law J; 2013; 68(4):449-65. PubMed ID: 24552082
    [No Abstract]   [Full Text] [Related]  

  • 40. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.